| Literature DB >> 27648725 |
D J Brinkman1,2, J Tichelaar1,2, T Schutte1,2, S Benemei3, Y Böttiger4, B Chamontin5, T Christiaens6, R Likic7, R Maˇiulaitis8, T Marandi9, E C Monteiro10, P Papaioannidou11, Y M Pers12, C Pontes13, A Raskovic14, R Regenthal15, E J Sanz16, B I Tamba17, K Wilson18, Tp de Vries1,2, M C Richir1,2, Ma van Agtmael1,2.
Abstract
European medical students should have acquired adequate prescribing competencies before graduation, but it is not known whether this is the case. In this international multicenter study, we evaluated the essential knowledge, skills, and attitudes in clinical pharmacology and therapeutics (CPT) of final-year medical students across Europe. In a cross-sectional design, 26 medical schools from 17 European countries were asked to administer a standardized assessment and questionnaire to 50 final-year students. Although there were differences between schools, our results show an overall lack of essential prescribing competencies among final-year students in Europe. Students had a poor knowledge of drug interactions and contraindications, and chose inappropriate therapies for common diseases or made prescribing errors. Our results suggest that undergraduate teaching in CPT is inadequate in many European schools, leading to incompetent prescribers and potentially unsafe patient care. A European core curriculum with clear learning outcomes and assessments should be urgently developed.Entities:
Mesh:
Year: 2016 PMID: 27648725 PMCID: PMC5260337 DOI: 10.1002/cpt.521
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN: 0009-9236 Impact factor: 6.875
Figure 1Left: Study flow diagram. Right: Map of the number of included medical schools by country.
Essential knowledge and skills in clinical pharmacology and therapeutics of European final‐year students (n = 895).
| Knowledge (MCQs | ||
|---|---|---|
| Pharmacological mechanisms of action | % (SD) | 79.3 (18.1) |
| Side effects | % (SD) | 79.4 (17.7) |
| Interactions and contraindications | % (SD) | 50.0 (20.9) |
| Total | % (SD) | 69.6 (14.9) |
|
| ||
| Total number of therapies |
| 4.195 |
| Appropriate | % (range) | 26.2 (5–52) |
| Suboptimal | % (range) | 27.6 (15–40) |
| Inappropriate | % (range) | 46.2 (15–76) |
| ‐ Not immediately harmful | % (range) | 81.1 (63–100) |
| ‐ Potentially harmful | % (range) | 15.2 (0–35) |
| ‐ Potentially lethal | % (range) | 3.7 (0–13) |
| Total number of prescriptions |
| 5.429 |
| Total number of prescribing errors |
| 5.104 |
| Number of prescriptions including errors |
| 2.771 (54.7) |
| Type of errors | ||
| ‐ Not indicated/inappropriate for indication | % | 9.1 |
| ‐ Less effective drug choice | % | 19.6 |
| ‐ Underdosing | % | 7.8 |
| ‐ Overdosing | % | 17.9 |
| ‐ Too short duration | % | 5.5 |
| ‐ Too long duration | % | 11.3 |
| ‐ Incorrect route | % | 1.4 |
| ‐ Incomplete/incorrect drug prescription | % | 18.0 |
| ‐ Protecting/preventing medication omitted | % | 3.0 |
| ‐ Drug group name | % | 2.3 |
| ‐ Inappropriate abbreviation | % | 0.9 |
| ‐ Therapeutic duplicity | % | 0.7 |
| ‐ Other | % | 2.5 |
MCQs, multiple‐choice questions.
Percent of the total maximum score with equal weighting per medical school.
Percent of the total number of drug therapies with equal weighting per school.
Percent of the total number of prescribing errors with equal weighting per school.
Figure 2Self‐reported confidence in prescribing skills according to WHO 6‐step method (n = 895).
Figure 3The median number of estimated hours devoted to various methods to teach clinical pharmacology and therapeutics during undergraduate curricula (interquartile range and 10–90 percentiles shown).
Figure 4Amount (a) and rating (b) of basic pharmacology, clinical pharmacology, and pharmacotherapy teaching in undergraduate medical curricula.
Types of curriculum for clinical pharmacology and therapeutics
| Type | Description |
|---|---|
| Mainly traditional learning curriculum | >50% of education consists of one or more of the following: lectures (formal), self‐directed learning (textbooks), oral and written exams, essays |
| Mainly problem‐based learning curriculum | >50% of education consists of one or more of the following: seminars (interactive), small working groups (case scenarios), role playing and patient simulation including OSCEs, clinics including prescribing for real patients |
| Mixed learning curriculum | Equal mixture (50/50%) of traditional learning and problem‐based learning |
OSCE, Objective Structured Clinical Examination.
Marking scheme adapted from the EQUIP classification scheme including examples of drug therapies prescribed by students
| Category | Subcategory | Description | Examples (related clinical case) |
|---|---|---|---|
| Appropriate | • A drug therapy is defined as appropriate if the correct drug, dose, dosage, duration, and route is chosen according to the European and/or local guidelines | • amoxicillin 500mg three times a day for 5 days per os (CAP | |
| Suboptimal | • The dose of drug therapy is slightly too high (half to two times the normal dose) for the condition being treated | • esomeprazole 40mg once daily (GERD | |
| • The dose of drug therapy is slightly too low for the condition being treated to produce the desired outcome | • paracetamol 1000mg twice daily (osteoarthritis | ||
| • The duration of drug therapy is slightly too long for the condition being treated | • amoxicillin 14 days therapy (CAP) | ||
| • The duration of drug therapy is slightly too short for the condition being treated to produce the desired outcome | • omeprazole 3 weeks (GERD) | ||
| • Second or third choice of drug is prescribed instead of first‐choice drug for the condition being treated (according to the local or (inter)national guidelines) | • ranitidine instead of omeprazole (GERD) | ||
| • Symptomatic drug therapy is prescribed without strong scientific benefits for the patient | • acetylcysteine (bronchitis | ||
| Inappropriate | Not immediately harmful | • The drug dose is too high (three times to four times the normal dose) for the condition being treated | • enalapril 20 mg once daily (hypertension |
| • The drug dose is too low for the condition being treated to expect a beneficial outcome | • amoxicillin 375mg once daily (CAP) | ||
| • The duration of the drug therapy is too long for the condition being treated resulting in drug overuse | • omeprazole life‐long (GERD) | ||
| • The duration of the drug therapy is too short for the condition being treated to produce the desired outcome | • valsartan 1 week (hypertension) | ||
| • Incorrect drug formulation for route of drug administration | • ceftriaxone per os (CAP) | ||
| • No drug therapy is prescribed although the condition requires initiation of drug therapy | • no additional analgesic prescribed (osteoarthritis) | ||
| • Omission of protective or preventive drug therapy | • NSAID without PPI (osteoarthritis) | ||
| • Unnecessary drug therapy is prescribed for which there is no valid medical indication | • amoxicillin (bronchitis) | ||
| • Duplicate drug therapy is prescribed without benefits for the patient | • two times salbutamol (bronchitis) | ||
| • The prescription lacked drug name, dose, dosage, duration, route, or included inappropriate abbreviations, or drug class instead of generic name, or was illegible | • ‘PPI’ (GERD) | ||
| Potentially harmful | • The drug dose is too high (four to ten times the normal dose) for the condition being treated with increased risk of adverse effects | • tramadol 500 mg once daily (osteoarthritis) | |
| • Unnecessary drug therapy is prescribed for which there is no valid medical indication and with increased risk of adverse effects | • amitriptyline (osteoarthritis) | ||
| • Intravenous drug therapy is prescribed while not medically necessary | • ceftriaxone intravenous (CAP) | ||
| • Duplicate drug therapy is prescribed with increased risk of adverse effects | • two times ibuprofen (osteoarthritis) | ||
| • Drug therapy could exacerbate the patient's condition including drug‐drug interaction or drug‐disease contraindication | • propranolol and asthma (hypertension) | ||
| Potentially lethal | • Serum drug levels are likely to be toxic based on common dosage guidelines | • naproxen 50 g (osteoarthritis) | |
| • Errors including decimal points or units resulting in severe toxicity | • salbutamol 200 mg (bronchitis) | ||
| • Drug therapy being administered has a high potential to cause cardiopulmonary arrest in the dose ordered | • amlodipine 300 mg (hypertension) |
CAP, mild community‐acquired pneumonia (pneumonia severity index I).
GERD, gastroesophageal reflux disease (grade A) not sufficiently responding to lifestyle changes.
Osteoarthritis not sufficiently responding to treatment with paracetamol.
Uncomplicated acute bronchitis.
Essential hypertension not sufficiently responding to hydrochlorothiazide 12.5 mg daily and lifestyle changes.